Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma (Q33397545)

26 July 2017

title

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1

David A Reardon

1 reference

26 July 2017

2

Timothy Cloughesy

1 reference

26 July 2017

3

Jeremy Rich

1 reference

26 July 2017

W K Alfred Yung

4

1 reference

26 July 2017

Lotus Yung

5

1 reference

26 July 2017

Clifford DiLea

6

1 reference

26 July 2017

Jerry Huang

7

1 reference

26 July 2017

Margaret Dugan

8

1 reference

26 July 2017

William Mietlowski

9

1 reference

26 July 2017

Andrea Maes

10

1 reference

26 July 2017

Charles Conrad

11

1 reference

26 July 2017

publication date

9 October 2011

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

69

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

281-287

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Review of the proliferation inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Dose‐Finding with Two Agents in Phase I Oncology Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

10.1007/S00280-011-1754-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1009222974

0 references

1 reference